Label-free relative quantification of alpha-2-macroglobulin site-specific core-fucosylation in pancreatic cancer by LC-MS/MS

Zhenxin Lin, Haidi Yin, Andy Lo, Mack Ruffin, Michelle A. Anderson, Diane M. Simeone, David M. Lubman

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

We describe a label-free relative quantification LC-MS/MS method for core-fucosylation in alpha-2-macroglobulin (A2MG) immunoprecipitated from human sera. The method utilizes endoglycosidase F partial deglycosylation to reduce glycosylation microheterogeneity, while retaining the innermost N-acetylglucosamine (GlcNAc) and core fucose. Precursor ion peak areas of partially deglycosylated peptides were obtained and site-specific core-fucosylation ratios based on the peak areas of core-fucosylated and nonfucosylated counterparts were calculated and evaluated for assay development. This assay was applied in a preliminary study of sera samples from normal controls and patients with pancreatic diseases, including pancreatic cancer and chronic pancreatitis. A2MG fucosylation levels at sites N396 and N1424 were found to decrease in both chronic pancreatitis and pancreatic cancer compared to normal controls. The two sites were identified by two peptides and their core-fucosylation ratios were found to be internally consistent. This method provides a platform to quantify fucosylation levels and can be used to study site-specific core-fucosylation aberrations in other glycoproteins for other diseases.

Original languageEnglish (US)
Pages (from-to)2108-2115
Number of pages8
JournalELECTROPHORESIS
Volume35
Issue number15
DOIs
StatePublished - Jan 1 2014

Fingerprint

alpha-Macroglobulins
Pancreatic Neoplasms
Labels
Assays
Chronic Pancreatitis
Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase
Glycosylation
Peptides
Fucose
Acetylglucosamine
Aberrations
Pancreatic Diseases
Glycoproteins
Ions
Serum

All Science Journal Classification (ASJC) codes

  • Analytical Chemistry
  • Biochemistry
  • Clinical Biochemistry

Cite this

Lin, Zhenxin ; Yin, Haidi ; Lo, Andy ; Ruffin, Mack ; Anderson, Michelle A. ; Simeone, Diane M. ; Lubman, David M. / Label-free relative quantification of alpha-2-macroglobulin site-specific core-fucosylation in pancreatic cancer by LC-MS/MS. In: ELECTROPHORESIS. 2014 ; Vol. 35, No. 15. pp. 2108-2115.
@article{53c35096433f44ce8c135d280d1489f8,
title = "Label-free relative quantification of alpha-2-macroglobulin site-specific core-fucosylation in pancreatic cancer by LC-MS/MS",
abstract = "We describe a label-free relative quantification LC-MS/MS method for core-fucosylation in alpha-2-macroglobulin (A2MG) immunoprecipitated from human sera. The method utilizes endoglycosidase F partial deglycosylation to reduce glycosylation microheterogeneity, while retaining the innermost N-acetylglucosamine (GlcNAc) and core fucose. Precursor ion peak areas of partially deglycosylated peptides were obtained and site-specific core-fucosylation ratios based on the peak areas of core-fucosylated and nonfucosylated counterparts were calculated and evaluated for assay development. This assay was applied in a preliminary study of sera samples from normal controls and patients with pancreatic diseases, including pancreatic cancer and chronic pancreatitis. A2MG fucosylation levels at sites N396 and N1424 were found to decrease in both chronic pancreatitis and pancreatic cancer compared to normal controls. The two sites were identified by two peptides and their core-fucosylation ratios were found to be internally consistent. This method provides a platform to quantify fucosylation levels and can be used to study site-specific core-fucosylation aberrations in other glycoproteins for other diseases.",
author = "Zhenxin Lin and Haidi Yin and Andy Lo and Mack Ruffin and Anderson, {Michelle A.} and Simeone, {Diane M.} and Lubman, {David M.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1002/elps.201300376",
language = "English (US)",
volume = "35",
pages = "2108--2115",
journal = "Electrophoresis",
issn = "0173-0835",
publisher = "Wiley-VCH Verlag",
number = "15",

}

Label-free relative quantification of alpha-2-macroglobulin site-specific core-fucosylation in pancreatic cancer by LC-MS/MS. / Lin, Zhenxin; Yin, Haidi; Lo, Andy; Ruffin, Mack; Anderson, Michelle A.; Simeone, Diane M.; Lubman, David M.

In: ELECTROPHORESIS, Vol. 35, No. 15, 01.01.2014, p. 2108-2115.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Label-free relative quantification of alpha-2-macroglobulin site-specific core-fucosylation in pancreatic cancer by LC-MS/MS

AU - Lin, Zhenxin

AU - Yin, Haidi

AU - Lo, Andy

AU - Ruffin, Mack

AU - Anderson, Michelle A.

AU - Simeone, Diane M.

AU - Lubman, David M.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - We describe a label-free relative quantification LC-MS/MS method for core-fucosylation in alpha-2-macroglobulin (A2MG) immunoprecipitated from human sera. The method utilizes endoglycosidase F partial deglycosylation to reduce glycosylation microheterogeneity, while retaining the innermost N-acetylglucosamine (GlcNAc) and core fucose. Precursor ion peak areas of partially deglycosylated peptides were obtained and site-specific core-fucosylation ratios based on the peak areas of core-fucosylated and nonfucosylated counterparts were calculated and evaluated for assay development. This assay was applied in a preliminary study of sera samples from normal controls and patients with pancreatic diseases, including pancreatic cancer and chronic pancreatitis. A2MG fucosylation levels at sites N396 and N1424 were found to decrease in both chronic pancreatitis and pancreatic cancer compared to normal controls. The two sites were identified by two peptides and their core-fucosylation ratios were found to be internally consistent. This method provides a platform to quantify fucosylation levels and can be used to study site-specific core-fucosylation aberrations in other glycoproteins for other diseases.

AB - We describe a label-free relative quantification LC-MS/MS method for core-fucosylation in alpha-2-macroglobulin (A2MG) immunoprecipitated from human sera. The method utilizes endoglycosidase F partial deglycosylation to reduce glycosylation microheterogeneity, while retaining the innermost N-acetylglucosamine (GlcNAc) and core fucose. Precursor ion peak areas of partially deglycosylated peptides were obtained and site-specific core-fucosylation ratios based on the peak areas of core-fucosylated and nonfucosylated counterparts were calculated and evaluated for assay development. This assay was applied in a preliminary study of sera samples from normal controls and patients with pancreatic diseases, including pancreatic cancer and chronic pancreatitis. A2MG fucosylation levels at sites N396 and N1424 were found to decrease in both chronic pancreatitis and pancreatic cancer compared to normal controls. The two sites were identified by two peptides and their core-fucosylation ratios were found to be internally consistent. This method provides a platform to quantify fucosylation levels and can be used to study site-specific core-fucosylation aberrations in other glycoproteins for other diseases.

UR - http://www.scopus.com/inward/record.url?scp=84905235161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905235161&partnerID=8YFLogxK

U2 - 10.1002/elps.201300376

DO - 10.1002/elps.201300376

M3 - Article

VL - 35

SP - 2108

EP - 2115

JO - Electrophoresis

JF - Electrophoresis

SN - 0173-0835

IS - 15

ER -